Manuscript accepted in Neuropharmacology
The manuscript titled “Perinatal fentanyl exposure drives enduring addiction risk and central amygdala gene dysregulation” was accepted in Neuropharmacology.
Congratulations!
Manuscript accepted in eNeuro
The manuscript titled “A Preclinical Alcohol Biobank: Samples from Behaviorally Characterized HS Rats for AUD Research” was accepted in eNeuro.
Congratulations!
U01 grant awarded with Dr. Abraham Palmer as a co-investigator
A new U01 grant from the National Institute on Drug Abuse (NIDA) was awarded to Dr. Paul Meyer, with Drs. Abraham Palmer and Leah Solberg Woods as co-investigators.
The grant is titled “Genetic substrates of cue-reactivity and cocaine motivation” and it will start August 1, 2025 and end on April 30, 2030.
Congratulations!
Daniel Munro participates in NASA study at Johnson Space Center
Palmer Lab member Daniel Munro is participating in a NASA study to test a denitrogenation protocol to reduce the risk of decompression sickness in astronauts during spacewalks!
Starting today, he will live for a week in an altitude chamber at Johnson Space Center in Houston, Texas with seven other test subjects and perform activities to simulate extravehicular activity (EVA) conditions. The results of this research will inform the design of Artemis missions to the moon and beyond.
Manuscript accepted in Molecular Psychiatry
The manuscript titled “Genome-wide association studies of lifetime and frequency of cannabis use in 131,895 individuals” was accepted in Molecular Psychiatry.
Manuscript accepted in Molecular Psychiatry
The manuscript titled “Genome-wide association study of delay discounting identifies 11 loci and reveals transdiagnostic associations across mental and physical health” was accepted in Molecular Psychiatry.
R21 grant awarded with Dr. Abraham Palmer as a co-investigator
A new R21 grant from the National Institute on Drug Abuse (NIDA) was awarded to Dr. Marsida Kallupi, with Dr. Abraham Palmer as co-investigator.
The 2-year grant is titled “Enhancing Addiction Severity Prediction by Modulating GABAergic Activity in the Central Amygdala of RATTACA Rats” and it will start July 15, 2025 and end on June 30, 2027.
Congratulations!
New U01 grant awarded to MPIs Pejman Mohammadi and Abraham Palmer
A new U01 grant from the National Institute on Drug Abuse (NIDA) was awarded to Dr. Pejman Mohammadi and Dr. Abraham Palmer.
The grant is titled “Deep Analysis of Transcriptome to Understand the Genetics of Substance Use Disorders in Rats” and it will start July 1, 2025 and end on March 31, 2030.
Congratulations!
Dr. Palmer organizes festschrift for Harriet de Wit
On June 27, 2025, Dr. Abraham Palmer presented at the Festschrift event held in honor of Harriet de Wit at the University of Chicago.
He co-organized the event with Hanna Molla (University of Chicago).
Dr. Palmer and Zachary Tatom attend annual RSA meeting in New Orleans
Dr. Abraham Palmer and Palmer Lab postdoc Zachary Tatom attended the 48th Annual Research Society on Alcohol (RSA) Scientific Meeting/ISBRA Congress in New Orleans, Louisiana from June 21-25, 2025.
Dr. Palmer served as Co-chair, Organizer, and Discussant for the Identifying Genes, Mechanisms and Therapeutic Targets for Alcohol Use Disorder: Progress From Forward and Reverse Genetics Symposium.
Zack presented a talk at the symposium titled “Anxiety Phenotype Components Predict Ethanol Consumption Magnitude and Progression in a Genetic Analysis with Diversity Outbred Mice.”
See the Photo Gallery for RSA 2025 photos!
